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Key points:  
Hazards regarding mortality and AML transformation in MDS diminish over time in 
higher risk, remain stable in lower risk patients.  
This change of hazard indicates time-dependent attenuation of power of basal risk 
scores, relevant for clinical decision making. 
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Abstract   
In myelodysplastic syndromes (MDS) evolution of risk for disease progression or death 
has not been systematically investigated despite being crucial for correct interpretation 
of prognostic risk scores. In a multicenter retrospective study we describe changes in 
risk over time, the consequences for basal prognostic scores and their potential clinical 
implications. Major MDS prognostic risk scoring systems (IPSS, IPSS-R, WPSS, LR-
PSS) and their constituent individual predictors were analyzed in 7,212 primary 
untreated MDS patients from the IWG-PM database. Changes in risk of mortality and of 
leukemic transformation over time from diagnosis were described. In higher risk MDS, 
hazards regarding mortality and AML transformation diminished over time from 
diagnosis, whereas they remained stable in lower risk patients. After approximately 3.5 
years, hazards in the separate risk groups became similar and essentially equivalent 
after five years. This fact led to loss of prognostic power of different scoring systems 
considered – more pronounced for survival. Inclusion of age resulted in increased initial 
prognostic power for survival and less attenuation in hazards. If needed for practicability 
in clinical management the differing development of risks suggested a reasonable 
division into lower and higher risk MDS based on the IPSS-R at a cut-off of 3.5 points. 
Our data regarding time-dependent performance of prognostic scores reflect the 
disparate change of risks in MDS subpopulations. Lower risk patients at diagnosis 
remain “constant lower risk", while "initially high risk" patients demonstrate decreasing 
risk over time. This change of risk should be considered in clinical decision making. 
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Introduction 
The myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders 
resulting in ineffective hematopoiesis in the bone marrow associated with peripheral 
blood cytopenias and a risk of developing acute myeloid leukemia (AML) in 
approximately one third of cases1. Due to its heterogeneous nature and wide range of 
clinical courses, classification and prognostication is of paramount importance for the 
management of this disease. Independent prognostic instruments have been developed 
over the years2 and function as additional staging systems. Most scoring systems 
assess prognosis at the time of diagnosis assuming stable predictability over the 
disease course. An earlier single center study has shown moderate loss of prognostic 
power over time in scoring systems using clinical parameters, whereas systems focusing 
on cytogenetics and comorbidity maintained prognostic power3. Recently, new 
prognostic scoring systems have been developed providing improved prognostication for 
MDS patients4-7. Previously, the comparison of scores was only provided from the time 
of diagnosis7 and the stability of risk over time and the clinical applicability for time points 
after diagnosis remain unclear. 
The aim of this multicenter retrospective study therefore was to assess the relative 
stability of the newly developed scoring systems over time, to compare the observed 
time-related changes in prognostic power among these systems and to relate these 
changes to the time-dependence of hazards. These data can then be applied to MDS 
populations with different risk for their clinical outcomes when evaluated over time after 
diagnosis and as they relate to their clinical implications.  
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Patients and Methods 
Patients 
This study is based on 7,212 untreated (i.e. they did not receive disease modifying 
treatment during MDS-phase - disease-specific treatment was allowed after progression 
to AML) primary MDS patients from 19 institutional databases comprising the 
International Working Group for Prognosis in MDS (IWG-PM), which generated the 
Revised International Prognostic Scoring System (IPSS-R) for MDS7 under the aegis of 
the MDS Foundation, Inc. in accordance with institutional review board approvals. 
Patient characteristics were well comparable with other MDS series: median age 71 
years, male gender 60%.  After a median follow up time of 4.0 years, median overall 
survival was 3.8 years (range 0.1-39.75, 95% confidence interval 3.7-4.0) and median 
time to transformation to AML was not reached with 25% of patients transforming to 
AML after 6.8 years. Patients were diagnosed and classified by French American and 
British (FAB) and/or World Health Organization (WHO) morphologic classifications; the 
cytogenetic pattern was classified by original IPSS subtypes8 and by the refined 
proposal that was integrated into the IPSS-R9. 
 
Investigated parameters and scoring systems 
First, single score components [hemoglobin, absolute neutrophil counts (ANC) and 
platelet count, bone marrow blast percentage, cytogenetics] and differentiating features 
for the IPSS-R (age, performance status, ferritin, LDH, ß-2microglobulin, marrow 
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fibrosis)7 were analyzed for stability of prognostic power over time. Then the following 
scoring systems were analyzed: IPSS8, IPSS-R and IPSS-RA (i.e. IPSS-R including 
age)7, the original WPSS applying transfusion need4, its modification using hemoglobin 
thresholds (“WPSS 2011”)10 as well as its modification including age (“WPSS-A”)11, and 
the low-risk MD Anderson Score (LR-PSS)5. For a detailed description and distribution 
of variables analyzed, see Table 1 and Supplement from reference 7. In the present 
analysis the IPSS-R7 was calculated for all cases (n=7212), whereas the WPSS-R11 was 
applicable only to patients classified by WHO criteria (n=5763) (i.e. missing a portion of 
cases present in the IPSS-R). Therefore, when comparing scores including WPSS, only 
WHO-classified patients were analyzed. 
Statistical Methods 
Time variations were described by the Cox-zph-test12, and by applying Dxy13, a measure 
of concordance for censored data, at different observation periods (landmarks). 
Smoothed hazard graphs for time intervals were calculated14. Cause-specific hazard 
was estimated for time to leukemic transformation, and for consistency the related 
Kaplan-Meier curves are based on these cause-specific hazards, i.e. they do not 
account for competing risks of death, as the aim was to describe the change of hazard 
with time, not the description of the cumulative incidence of transformations15. The 
potential influence of scoring weights on stability was analyzed by the creation of 
hypothetical time-specific scores as landmark reference scores. 
The following specific hypotheses connected to the interpretation of results required 
particular methods: Most scores are based on Cox-models. In these models, a certain 
set of potential predictors is selected, and the model estimates optimal weights, to form 
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a prognostic score as a weighted sum of these potential predictors. Since the majority of 
events occurred early, the estimation was dominated by the initial period after diagnosis. 
Our question of interest was to determine whether weights, optimized for later periods 
would improve prediction in these later periods. Therefore, hypothetical scores were 
estimated for the landmarks 12 to 48 months.  
Since the aim of this project did not imply clinically plausible null hypotheses, formal 
significance tests were not considered appropriate.  All analyses were performed using 
the open source software R version 3.1.2 16, including the packages “survival“17, and 
“bshazard“14. For an additional discussion of methods and models used, see the 
Supplemental methodological material. 
 
Results 
Changes in the subgroup specific hazards over time 
Changes of hazard over time are shown by smoothed hazard plots, Figure 1A, using 
IPSS-R for WHO classified patients, serving as an example. Smoothed hazard plots 
basically contain the same information as the corresponding Kaplan-Meier curves 
(Figure 1B) The information is displayed in a different form to better visualize changes in 
risk at different time intervals. 
The enlarged section of the survival curves by IPSS-R (Figure 1B) shows, for example, 
that the curve for "very high" risk starts at 1.0 (i.e., 100%) (at two months because stable 
disease for two months was one of the inclusion criteria for the IPSS-R) and declines to 
about 0.9 (i.e., ca. 90%) after one month (i.e., after 3 months from diagnosis). That 
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means the initial mortality is 10% per month. The smoothed hazard for "very high" risk 
roughly indicates 0.1 (i.e. 10%) hazard (roughly interpretable as 10% mortality per 
month) in the beginning (see top arrow in Figure 1A). This is consistent with data 
represented by the Kaplan-Meier-curve. 
However, after 30 months the hazard plot (Figure 1A, middle arrow) shows .05, i.e. a 5% 
monthly mortality for the very high-risk group. While a Kaplan-Meier-curve shows the 
estimated proportion of persons still alive at each point in follow up time, the hazard plot 
shows the estimated proportion dying in a defined interval (here one month), given that a 
person is still alive at the start of the interval of interest. The fact that the force of 
mortality in the very high risk group decreases from 10% per month to 5% per month 
after about 2.5 years is clearly visible in the hazard plot, but not readily seen in the 
survival curve. 
For the entire sample (black dashed line, lower arrow), the hazard plot shows 2% 
mortality per month after diagnosis, and about 1% after 120 months. It can be seen that 
the mortality risks of the remaining patients for all risk groups are similar after about 60 
months. The graph illustrates that similarity of risks derives mainly from a decline in the 
higher risk groups (IPSS-R very high and high), whereas the mortality risk in the lower 
risk groups (IPSS-R low and very low) remains essentially unchanged. 
In Figure 2, the typical Kaplan-Meier plots are shown adjacent to hazard plots to 
facilitate comparison and to visualize the proportion of concerned patients at different 
time points. For a detailed view of individual scores, enlarged single figures are available 
in the supplemental material (Supplemental figure 1, A-T). The prognostic power of a 
score, as measured in this project by Dxy, results from the differences in the hazards of 
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risk categories. Consequently, the attenuation of these hazards with time reduces the 
time-specific prognostic power of the score. The more similar the hazards of risk 
categories are from a specific time point onwards, the less prognostically informative is 
the original assignment to a category. 
Change in the subgroup specific hazards over time for prognostic scores  
Attenuation of hazards over time was evident for all scoring systems. After 
approximately 3.5 years, hazards in the separate risk groups become similar and 
essentially equivalent after five years (see hazard plots in Figure 2). Almost all scores 
similarly lost prognostic power over time from diagnosis, so that the relative ranking 
remained virtually unchanged (Figure 3). Scores with high initial prognostic power, even 
if decreasing over time, retained a greater prognostic capacity than initially weaker 
scores (see Table 1). Compared to evaluation of survival, we observed a weaker decline 
of prognostic power with respect to time to transformation to AML.  
IPSS-R vs IPSS and FAB vs WHO 
Figure 3 demonstrates that the prognostic power of the IPSS-R after about 9 months 
remains as high as that of the original IPSS at diagnosis for both endpoints. Similarly, 
the IPSS-RA maintains a comparable power until around 14 months after diagnosis (see 
gray arrows in Figure 3). The IPSS-R performs generally better if the patient sample is 
restricted to WHO-defined-MDS (excluding oligoblastic AML) (see Table 1, line “IPSS-R 
WHO only”). 
WPSS 
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The WPSS variants show high initial prognostic power with loss in power over time, 
similar to that of other scoring systems. A meaningful comparison with the IPSS-R, 
necessarily based on WHO classifiable patients only, demonstrates similar initial high 
prognostic power and attenuation over time. 
Inclusion of age in prognostic scoring systems 
Inclusion of patient´s age results in higher initial prognostic power and better stability in 
predicting survival but not for time to AML progression (see comparison of scores with 
and without age adjustment in Table 1 and Figure 3A). 
Stability of scores in lower vs higher risk patients 
Scores applied to lower risk MDS only show generally lower prognostic power (because 
of less risk variation), but remain more stable over time (see Table 1, lines “LR-PSS in 
LR” and “ IPSS in LR”), because they are less affected by the attenuation of subgroup 
specific hazards (Figures 4B, 4D). This is seen for both the LR-PSS - initially derived 
from IPSS low and intermediate-1 patients5 - and for the IPSS-RA, if restricted to the 
very low/low/intermediate risk patients according to IPSS-R (see Figures 4A, 4C for 
survival curves). This ad hoc definition was used only for affording a better comparison 
of the predictive power of the IPSS-R and the LR-PSS. In contrast, “high/very high risk 
categories” show a sharp decline in risk over time (e.g., IPSS-R in Figure 2 F, H) for 
both endpoints. In lower risk MDS, a slight increase of mortality risk occurs due to age 
(Figures 4C, 4D), whereas no similar effect is observed for time to transformation 
(Figures 2 K, 2L). 
Decline of prognostic power over time in potential prognostic variables 
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Decline of prognostic power for single potential prognostic variables as measured by 
Dxy is tabulated in Table 1. Bone marrow blast percentage is the strongest single 
predictor. Its predictive loss over time is in line with most other parameters and scores. 
Cytogenetic pattern is of high importance at time of diagnosis with steady loss of 
prognostic power. Beta-2 microglobulin and performance status (only available for a 
subset of patients) seem to have moderate, but stable influence on survival and 
increasing influence on time to progression.  As a plausibility check of the analysis, 
conversely, age showed growing negative impact on survival, although not on time to 
AML progression. 
Improvement by hypothetical time-specific scores 
Given that most potential prognostic variables exhibit loss of prognostic power over time, 
we investigated the effect of assigning different weights to score-constituting 
components for time-specific Cox models. See Supplemental Figure 2 for weights (A, B) 
and resulting curves (C, D). Dxy values for hypothetical scores for the landmarks 1 to 4 
years (overall survival) are shown in Supplemental Table 1. These landmark reference 
scores do not show higher prognostic power for target times, but rather attenuation of 
prognostic power.  
Consequences for dichotomization into lower risk versus higher risk MDS 
Based on prognostic power and on the differing declines of hazards in IPSS-R 
categories, the optimal dichotomization into just two risk categories – as usually 
employed in clinical practice – lower risk versus higher risk MDS patients – is the 
division obtained by using an IPSS-R score of ≤3.5 vs >3.5 points as a cut off.  
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At time of diagnosis, the Dxy for dichotomization at this cut off is 0.33 for overall survival 
and 0.44 for time to transformation, respectively, versus 0.31 and 0.37 if cutting at IPSS-
R very low/low/intermediate versus high/very high risk groups.  Loss of prognostic power 
at different time points for both approaches can be seen in Table 1.  Figure 5, which 
indicates the respective Kaplan-Meier curves for overall survival (A) and respective 
hazards plots (B) for patients with an IPSS-R score of ≤3.5 vs >3.5 points, regarding 
prognostic power also clearly demonstrates this dichotomy, showing good separation of 
patients with initially higher but declining risk versus patients with constant lower risk.  
The lower risk group proposed now includes a smaller proportion of cases than the 
original IPSS lower risk group, consequently assigning more patients to the higher risk 
group. 
 
Discussion 
MDS have been described as a spectrum of dynamic disorders, where clonal evolution 
identified at a cytogenetic and molecular level may trigger progression18-19. On the other 
hand, time of disease progression may be heterogeneous1. Risk for progression and 
survival may be estimated by risk-based categorization, which is generally performed at 
the time of diagnosis2. Recently, prognostic scoring systems have been substantially 
improved by refined inclusion and addition of parameters based on the use of larger, 
comprehensive databases. In addition, their use also for treatment decisions is 
recommended in disease management guidelines20-21.  However, data regarding the 
stability of risk scores over time are scarce3.  
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When using prognostic risk scoring systems in clinical daily practice, we assume 
implicitly that the risk within a specific risk category remains constant over the entire 
course of the disease. However, the present study showed that all the scoring systems 
we evaluated for MDS risk categories discriminated better at time of diagnosis compared 
to later time points (Figure 3, Table 1). In detail, our data demonstrated significant time-
dependent changes in the risk for both overall survival and leukemic transformation 
during elapsing time, which differed for specified patient populations (Figure 2). For 
higher-risk patients, the mortality risk declined more sharply over time, approaching that 
observed in lower-risk MDS, whereas for lower-risk patients the mortality risk remained 
essentially unchanged during follow-up.  
One potential explanation for this finding is, that the risk for AML transformation, which 
has a greater impact in the high risk subset of patients, decreases more dramatically 
compared to overall survival (Figure 2 F, H). In contrast, age-related risk of death, which 
has a more pronounced effect on mortality in lower-risk patients, increased with time 
(Table 1). Risk attenuation is at least partially caused by selective loss of higher-risk 
patients over time.  This loss may be an event such as death or leukemic transformation. 
In addition, a selection bias cannot be ruled out: the IWG-PM data set used for 
developing the IPSS-R only includes untreated patients and it is most likely that a 
greater proportion of higher-risk compared to lower-risk patients is actively treated with 
passing time from diagnosis, and thus selectively excluded from this study.  As changes 
in risk over time may stem from disease-specific and also from patient-related factors 
such as comorbidities, loss of prognostic power over time may be not due to a poor 
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quality of the scoring systems analyzed but to inherent survival dynamics of the MDS 
patient population. 
Theoretically, loss of prognostic power could also result from suboptimal weights of 
score components. We ruled out this possibility by providing hypothetical scores, 
optimized for later time intervals comparable to landmark analyses, and observed that 
these hypothetical scores lost prognostic power in a comparable fashion (Supplemental 
Table 1). In addition, as single parameters decline to a similar extent, better weighting of 
these variables at time of diagnosis did not mitigate the decline of prognostic power of 
scores over time (Table 1).  Data using somatic mutational molecular parameters with 
potential for prognosis18,21,22 will be of much interest for future analysis. The potential 
stability of such mutations over time requires further study.  
As loss of stability in prognostic scores exists, the question of the best approach for 
patient re-evaluation arises. Conventionally, the time of first bone marrow examination 
with features defining MDS is accepted as the time of diagnosis23. On the assumption 
that the impact of features changes little, and remembering different stability of hazards 
in different risk categories, scoring systems such as the IPSS-R may be used for re-
evaluation after diagnosis, at time points where still clinically meaningful conclusions can 
be drawn from risk score categories. Re-evaluation could be done at specific intervals 
established according to clinical needs (e.g., every six months for higher risk patients 
and at longer intervals for lower risk patients).  
Our data on the differential development of risks for the single score subgroups suggest 
also for the first time a reasonable division into lower risk and higher risk MDS into two 
groups based on the IPSS-R, a fact that may be valuable for design of clinical trials and 
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for patient management. As described, lower risk MDS have virtually constant risk for 
both endpoints, whereas in higher-risk cases risk diminishes substantially over time. If 
the aim is optimal prognostic separation of lower risk versus higher risk patients, then a 
dichotomization based on 3.5 scoring points of the IPSS-R raw score  (i.e. ≤3.5 vs >3.5) 
yielded the best results. This also best represents the different changes in risk 
categories over time (Figure 5, Table 1). In particular, all patients scoring >3.5 points fit 
well into the higher risk group. The proportion of lower risk patients using this 
dichotomization is smaller compared to the lower risk group of the original IPSS, which 
was heterogenous and contained patients with higher risk. 
Our results serve to underscore the ongoing processes occurring during the course of 
the disease and should help guide clinical decisions in MDS. One interpretation relates 
to a new perception of higher and lower risk MDS where lower risk patient subgroups 
may be better described as a group of patients with “constant lower risk" (risk remaining 
the same over time) whereas the term "initially higher risk" MDS (but with decreasing 
risk over time) fits higher risk subgroups better. Although our data are derived from 
“untreated” MDS patients, this is a representative patient cohort since the majority of 
MDS patients are still provided with supportive care without disease-modifying 
treatment24, 25. Future analysis of patients receiving treatment and comparison with the 
data presented herein are planned and may indicate the impact of therapy. 
The following clinical recommendations can be derived from our data: If a patient is 
initially categorized as high risk, options for disease-modifying treatment should be 
considered immediately, and if deemed appropriate, a decision for treatment should be 
made as early as possible. If in contrast, due to comorbidities, decreased performance 
17 
 
status, clinical stability or other reasons a high risk patient does not receive disease-
modifying treatment at time of diagnosis, but remains in stable condition for a prolonged 
period, re-evaluation for a specific treatment should be re-considered at that time. For 
lower risk patients it should be noted that risk remains relatively constant over time, 
therefore surveillance and ongoing re-evaluation should be maintained long term. 
In conclusion, our data describe the change of risk within prognostic score categories 
over time in MDS and their effects on the construction and interpretation of prognostic 
scoring systems. Clinicians should be aware of these facts when assessing patients 
after time intervals and when making treatment decisions. This study clearly 
demonstrates that a cut-off point of 3.5 in the IPSS-R scoring system is the best for 
segregating MDS patients into two risk groups – lower risk and higher risk – for 
therapeutic purposes, although a loss of prognostic power compared to the use of raw 
score data or the five IPSS-R category approach should be noted. Since the statistical 
tools used in our analysis may be applied to other prognostic scoring systems, it will be 
of interest to determine whether similar changes of risk over time are observed in other 
disease entities. 
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Legends for figures and table 
Figure 1. Survival of IPSS-R classified patient subgroups using smoothed hazard 
plots (A) and corresponding Kaplan-Meier curves (B) (representative example). 
Smoothed hazard plots more clearly demonstrate changes in risk at different time 
intervals than do Kaplan-Meier plots. The smoothed hazard for "very high" risk indicates 
10% monthly mortality risk in the beginning (top arrow in Figure 1A) in agreement with 
the Kaplan-Meier curve. After approximately 30 months (middle arrow) 5% monthly 
mortality for the very high-risk group is shown, not clearly visible in the Kaplan-Meier 
curve. The mortality risks of the remaining patients for all risk groups are similar after 
approximately 60 months.  Note that the time scale in (B) is expanded to improve 
visibility of the decline in the first year. 
vhr = very high-risk, all patients = bold black dotted line. 
Figure 2: Comparison of Kaplan-Meier curves and hazard plots for specific risk 
scoring systems, both for overall survival (columns 1-2) and for time to leukemic 
transformation (columns 3-4). Colors for risk groups are assigned in the order of risk 
from lowest to highest: green, gray, yellow, red, blue. All patients: bold black dotted line.  
For leukemic transformation the cause-specific hazard is shown. The curves for time to 
leukemic transformation correspondingly are based on the cause-specific hazard (and 
are not cumulative incidence curves). 
Attenuation of hazards occurred over time after diagnosis in all scoring systems. After 
approximately 3.5 years, hazards in the separate risk groups became similar, and 
essentially equivalent after five years.  Note differing time scales for the Kaplan-
Meier and hazard plots. 
For a detailed view of individual scores, enlarged color single figures are available in the 
supplemental material (Supplemental Figure 1 A-T) 
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Figure 3: Comparison of change in prognostic power for specific scoring systems: 
A for overall survival, B for time to leukemic transformation (based on WHO-
classified patients).  
The figure demonstrates that nearly all scores lost prognostic power over time, with the 
relative ranking remaining virtually unchanged.  Scores with high initial prognostic power 
remained prognostically stronger than initially weaker scores. The prognostic power of 
the IPSS-R after about 9 months and the IPSS-RA until around 14 months remain as 
high as that of the original IPSS at diagnosis (gray arrows). Inclusion of patient´s age 
results in higher initial prognostic power and better stability in predicting survival but not 
for time to AML progression, represented by results from IPSS-R(A) and WPSS(A) 
versions which included age (in Fig 3A). 
 
Figure 4. Stability of scores in lower risk patients: (Kaplan-Meier curves and 
hazard plots) 
Overall survival shown by Kaplan-Meier curves (A, C), and hazard plots (B, D) using LR-
PSS (A, B) and IPSS-RA (C, D). The figure demonstrates that scores applied to lower 
risk MDS only have lower prognostic power, but remain more stable over time, and are 
less affected by the attenuation of subgroup specific hazards (Figure 4B, 4D). This is 
seen for both the LR-PSS and for the IPSS-RA, with both scores restricted to the IPSS-
R very low/low/intermediate patients (see Figure 4A, 4C for survival curves). An increase 
of mortality risk related to age is shown (Figure 4C, 4D).  LR-PSS categories:  C1: score 
0-2, C2: score 3-4, C3: score 5-7. Note differing time scales for the Kaplan-Meier 
and hazard plots. 
 
Figure 5:  Dichotomized separation of lower vs higher risk MDS patients in IPSS-R 
stratified patients: (Kaplan-Meier curves and hazard plots: Kaplan-Meier curves for 
overall survival (A) and respective hazards plots (B) for patients with an IPSS-R score of 
≤3.5 vs >3.5 points (A-B) yielding the best results regarding prognostic power and 
showing a good separation of patients with initially higher but declining risk vs patients 
with constant lower risk. Note differing time scales for the Kaplan-Meier and hazard 
plots. 
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Table 1: Dxy values for specific scores and single clinical predictors 
Dxy is a measure of correlation varying between -1 and 1, with 0 indicating no  
correlation, and 1 perfect concordance of prognosis and survival, respectively 
time to transformation (see also the short explanation of Dxy in the supplement). 
Dxy values were tabulated conditional on minimum observation time for potential 
predictors and composite scores. Changes in Dxy values are consistent with hazard 
plots Figures 1-2 and 4-5 and show similar loss of prognostic power over time. Scores 
with high initial prognostic power, even if decreasing over time, remained prognostically 
stronger than initially weaker scores. With respect to single parameters, bone marrow 
blast percentage is the strongest single predictor. Its predictive loss over time is 
consistent with most other parameters and scores. Cytogenetic pattern is of high 
importance at time of diagnosis with steady loss of prognostic power. Age showed 
growing negative impact on survival, although not on time to AML progression. 
For hemoglobin, neutrophils, platelets and bone marrow blasts the cut points were those 
used for the IPSS-R. Age groups were categorized ≤55, >55 to ≤65, >65 to ≤75, >75 to 
≤80 and >80. For serum LDH and beta-2 microglobulin the upper limit of normal was the 
cut point; for serum ferritin 350ng/ml was the chosen cut point. Cytogenetic categories 
are those used in the IPSS-R. “In LR” denotes application of LR-PSS and IPSS-R on 
lower risk patients (i.e. IPSS-R very low, low, intermediate) only. IPSS-R WHO: IPSS-R 
exclusively applied to patients classifiable according to WHO. For dichotomization in two 
groups with higher vs lower risk patients dxy for combined IPSSR very low, low, 
intermediate versus high, very high (IPSS-R vlli/hvh) and for a cut off at 3.5 IPSS-R 
score points (IPSS-R-LH<=3.5/>3.5) are tabulated.  
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Table 1. Dxy values for specific scores and single predictors 
 
Dxy values for specified minimum observation times 
 For overall survival For time to transformation 
 
Time after diagnosis 
(months) 
0 12 24 36 48 60 0 12 24 36 48 60 
Scoring System 
IPSS 0.37 0.30 0.22 0.16 0.11 0.07 0.49 0.38 0.34 0.26 0.25 0.20
IPSS-R 0.43 0.35 0.27 0.20 0.14 0.08 0.53 0.42 0.38 0.31 0.24 0.07
IPSS-RA 0.46 0.38 0.31 0.26 0.22 0.18 0.53 0.43 0.38 0.32 0.25 0.13
WPSS 0.44 0.36 0.29 0.25 0.18 0.21 0.59 0.48 0.39 0.35 0.30 0.22
WPSS 2011 0.41 0.34 0.25 0.18 0.14 0.11 0.53 0.45 0.40 0.34 0.33 0.22
WPSS A 0.44 0.38 0.31 0.24 0.20 0.19 0.52 0.46 0.40 0.33 0.27 0.22
LR-PSS 0.27 0.25 0.25 0.20 0.18 0.19 0.26 0.23 0.24 0.18 0.16 0.17
LR-PSS in LR 0.21 0.20 0.21 0.18 0.18 0.18 0.16 0.18 0.20 0.14 0.12 0.10
IPSS-RA in LR 0.28 0.26 0.25 0.24 0.23 0.19 0.37 0.32 0.28 0.25 0.21 0.09
IPSS-RA WHO only 0.48 0.40 0.34 0.28 0.23 0.20 0.55 0.47 0.40 0.35 0.28 0.15
IPSS-R vlli/hvh 0.31 0.20 0.12 0.06 0.02 0.01 0.37 0.24 0.19 0.13 0.08 0.05
IPSS-R-
LH<=3.5/>3.5 
0.33 0.26 0.19 0.13 0.07 0.03 0.44 0.33 0.29 0.25 0.19 0.06
Predictor 
Hemoglobin 0.21 0.17 0.16 0.11 0.08 0.05 0.16 0.12 0.12 0.08 0.06 0.08
Neutrophils 0.11 0.09 0.07 0.04 0.03 0.02 0.16 0.15 0.12 0.10 0.05 0.01
Platelets 0.23 0.14 0.09 0.04 0.03 0.04 0.17 0.11 0.07 0.01 -0.01 0.00
Bone marrow blasts 0.30 0.26 0.18 0.13 0.10 0.06 0.48 0.38 0.30 0.27 0.25 0.12
Age 0.09 0.11 0.16 0.19 0.22 0.26 0.04 0.02 0.05 0.03 -0.03 0.16
ECOG 0.16 0.14 0.11 0.06 0.09 0.08 0.10 0.07 0.05 0.12 0.23 0.13
Ferritin 0.15 0.11 0.08 -0.01 0.03 0.01 0.11 0.08 -0.01 0.06 0.01 0.14
LDH 0.12 0.09 0.07 0.04 0.02 0.01 0.12 0.09 0.07 -0.01 0.01 0.08
Beta-2 microglobulin 0.14 0.14 0.14 0.15 0.11 0.10 0.02 0.07 0.04 0.01 0.00 0.38
Bone marrow fibrosis 0.04 0.04 0.05 0.04 0.01 0.02 0.05 0.03 0.09 0.00 0.01 0.05
Cytogenetic 
categories 
0.25 0.14 0.09 0.06 0.02 0.00 0.28 0.19 0.17 0.14 0.06 0.06
 
  
 
